Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study

Australian Catholic University (ACU)

Status: Enrolling

Conditions: Type 2 Diabetes Mellitus (T2DM); Obesity

Study type: Observational

Funder types: Other

Identifiers

NCT07001553

2025-4090H

Details and patient eligibility

About

An observational study of those who have been prescribed a GLP-1 agonist therapy (yet to commence), for either weight or diabetes management, and are willing to complete dietary records and questionnaires of behaviour and psychosocial health.

Full description

Forty individuals (20 for weight management, 20 for diabetes management) living in Australia who have been prescribed a GLP-1 agonist (no previous prescription or no use in the previous 6 months) will be recruited to participate over the initial 3 months of their treatment. Assessments will occur remotely (online) at baseline, 2 weeks, 1 month and 3 months. Optional body composition assessments will be provided at baseline and 3 months for those based in Melbourne, Australia.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 18+ years old
• Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months
• The primary reason for commencing the medication will be for diabetes or weight management
• Willing to participate in dietary recall and questionnaires

Exclusion criteria

• Aged under 18 years,
• used a GLP-1 agonist medication in the previous 6 months,
• unwilling or unable to provide dietary recalls
• non-English speaking.

Trial design

40 participants in 2 patient groups

Weight management

Description:

Prescribed GLP-1 agonist therapy primarily for weight management

Type 2 diabetes

Description:

Prescribed GLP-1 agonist therapy primarily for glycemic management